查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466560

胰臟癌藥物市場：按類型、產品、應用分類 - 全球預測 2024-2030

Pancreatic Cancer Therapeutics Market by Type (Endocrine Pancreatic Cancer, Exocrine Pancreatic Cancer), Product (Chemotherapy, Gene Therapy, Immunotherapy), End-Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

胰臟癌治療市場規模預計2023年為46.7億美元，2024年達51.4億美元，預計2030年將達到90.9億美元，複合年成長率為9.95%。

胰臟癌藥物包括多種用於控制和對抗胰臟癌的治療方法，胰臟癌以其侵襲性和嚴峻的預後而聞名。這種惡性的治療方法包括手術、放射線治療、化療、標靶治療、免疫治療和旨在緩解症狀和改善患者生活品質的支持性治療。由於人口老化、生活方式相關危險因子和遺傳易感性等因素，胰臟癌盛行率不斷上升，推動了對治療胰臟癌藥物的需求。此外，政府旨在擴大獲得負擔得起的胰臟癌治療的支持性政策正在擴大患者的治療選擇範圍。然而，複雜的報銷情況以及臨床試驗無法提供有用且可靠的結果引起了人們對治療準確性和有效性的擔憂。此外，對這種疾病的生物學的理解也取得了進展，導致了標靶治療藥物和個人化醫療方法的發展。這些治療方法旨在抑制促進胰臟癌細胞生長和轉移的特定途徑和機制。

主要市場統計
基準年[2023] 46.7億美元
預測年份 [2024] 51.4億美元
預測年份 [2030] 90.9億美元
複合年成長率（%） 9.95%

外分泌型胰臟癌的快速進展需要快速開發治療方案

胰臟神經內分泌腫瘤（NET），也稱為內分泌胰臟癌或胰島細胞腫瘤，是一種涉及胰臟中稱為胰島細胞的內分泌細胞快速異常生長的癌症。此類癌症的治療通常涉及手術切除癌細胞或胰臟的主要部分和尾部。此外，對於無法透過手術切除的腫瘤，可以採用化療和荷爾蒙療法的組合。外分泌胰臟癌（腺癌）是在攜帶胰液並幫助消化的導管內的胰臟組織中形成的癌症。然而，外分泌胰臟癌比內分泌胰臟癌進展得更快。

產品擴大了核准的化療方案的數量

化療涉及全身施用抑制癌細胞生長的藥物，仍是胰臟癌治療的重要支柱。這些細胞毒性藥物透過口服或注射給藥，但它們會產生副作用，因為它們無法區分惡性和正常細胞。然而，化療是治療方法的重要組成部分，並與其他策略一起使用以改善患者預後。基因治療是一種尖端技術，將新的遺傳物質引入患者的細胞中，以糾正導致癌症生長的缺陷基因或引入引發針對癌細胞的免疫反應的基因。目前，胰臟癌的基因治療主要是探索性的，僅限於臨床研究。免疫療法是一個快速發展的領域，利用人體的免疫防禦來對抗癌症。胰臟癌治療，包括查核點抑制劑、治療性疫苗和過繼性細胞療法，因其有效靶向癌細胞的能力而受到密切關注。免疫療法治療胰臟癌的效果各不相同。然而，正在進行的研究正在評估其潛力，特別是對於具有某些遺傳標記的患者。放射線治療是一種使用高能量粒子消滅癌細胞的技術，可作為單一治療方法或與外科手術聯合治療胰臟癌。立體定位放射治療 (SBRT) 等技術進步提高了放射治療的精確度，並最大限度地減少了對健康組織的附帶損害。對於早期胰臟癌，完全切除腫瘤的手術是首選方法。各種手術技術，例如惠普爾手術和遠端切除術，是由腫瘤的胰臟位置決定的。手術的可用性取決於癌症的階段和患者的健康狀況，化療和放射線治療通常結合使用以最佳化結果。標靶治療透過精確抑制特定的分子異常或參與腫瘤進展的途徑，對癌症提供更微妙的攻擊。

最終用途：擴大胰臟癌治療研究機構的合作研究和研究計劃

該診所提供個人化醫療，重點在於化療和患者追蹤。然而，醫院提供先進的手術技術和術後護理設施，使其成為為胰臟癌患者提供全面護理的核心。醫院對於進行惠普爾手術等大型手術至關重要，這對於治療可手術的胰臟癌至關重要。研究和學術機構正在與生物製藥公司合作開發和測試新的治療方法。此外，它為實證實踐奠定了基礎，有助於全面了解疾病管理，從而改善藥物和護理策略。

區域洞察

美洲地區，特別是美國和加拿大，具有強大的臨床管線、高醫療保健支出以及多家大型製藥公司的存在。美國食品藥物管理局(FDA) 已向多種胰臟癌藥物核准快速通道、突破性療法和孤兒藥資格，加快了監管核准流程。德國、法國、英國等歐洲國家醫療費用高、醫療設施先進、報銷政策優惠。歐洲藥品管理局 (EMA) 在核准新治療方法發揮關鍵作用，對市場成長產生積極影響。私營和公共機構之間的密切合作正在推動癌症治療研究的創新。中國、日本、印度和韓國等亞太國家的患者人數不斷成長，人們對癌症疾病的認知不斷提高，這推動了對治療方案的需求。印度等國家的學名藥本地生產不斷增加，促進了區域市場的動態。

FPNV定位矩陣

FPNV定位矩陣對於評估胰臟癌藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對胰臟癌治療市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.胰臟癌治療藥物市場規模及預測如何？

2.胰臟癌治療藥物市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3.胰臟癌治療藥物市場的技術趨勢和法規結構是什麼？

4.胰臟癌治療藥物市場主要廠商的市場佔有率如何？

5.進入胰臟癌藥物市場合適的型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球胰臟癌發生率正在上升
      • 政府努力擴大胰臟癌治療選擇
    • 抑制因素
      • 難以獲得危險藥品召回和報銷選擇
    • 機會
      • 提高胰臟癌藥物療效的研究舉措和進展
      • 胰臟癌治療藥物的核准和癌症治療藥物的核准
    • 任務
      • 胰臟癌治療方案的局限性和併發症以及缺乏訓練有素的醫療專業人員
  • 市場區隔分析
    • 類型：外分泌胰臟癌的快速進展需要快速部署治療方案
    • 產品：擴大核准的化療方案的數量
    • 最終用途：擴大胰臟癌治療研究機構之間的合作與研發活動
  • 市場趨勢分析
    • 由於關鍵參與者的強大存在和支持​​性的監管環境，胰腺癌藥物在美洲取得了進展
    • 透過加強對亞太地區癌症研究機構聯合研發活動和新治療方法臨床試驗的支持，加速癌症研究進展。
    • 研究人員、資助機構和監管機構的共同努力為歐洲、中東和非洲地區的胰臟癌帶來了新的治療方法
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章胰臟癌治療藥物市場：依類型

  • 內分泌胰臟癌
  • 外分泌胰臟癌

第7章胰臟癌治療藥物市場：依產品

  • 化療
  • 基因治療
  • 免疫療法
  • 放射治療
  • 外科手術
  • 標靶治療

第8章胰臟癌治療藥物市場：依最終用途分類

  • 癌症中心/診所
  • 醫院
  • 調查機構

第9章 北美和南美胰臟癌藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區胰臟癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲胰臟癌藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Trishula Therapeutics 開始在第一線轉移性胰臟癌患者中進行抗 CD39 抗體 TTX-030 的 2 期試驗
    • Risata 獲得治療胰臟癌的孤兒藥資格
    • PanCAN 宣布新的高級研究投資
    • Prestige Biopharma 與 Imagion Biosystems 簽署合作協議，開發胰臟癌早期診斷平台
    • TriSalus Life Sciences 完成與 MedTech Acquisition Corporation 的合併
    • 百時美施貴寶透過收購 Mirati Therapeutics 加強腫瘤學產品組合併使其多元化
    • 安斯泰來製藥 ( Astellas Pharma) 和 Poseida Therapeutics 宣布策略性投資，支持 Poseida 創新癌細胞療法的努力
    • FDA 指定 Zenocutuzumab 突破性治療 NRG1+ 胰臟癌
    • FDA核准TME Pharma 胰臟癌治療試驗的 IND
    • GenesisCare 在 Lee Health 區域癌症中心安裝 ViewRay MRIdian MRI 導引放射治療系統
    • 國家撥款 300 萬美元用於胰臟癌研究
    • Leap Therapeutics 收購 Flame Biosciences
    • Caladrius Biosciences 和 Cend Therapeutics 宣布完成合併並組成 Lisata Therapeutics
    • Fes Therapeutics 融資 4,700 萬美元用於推進癌症臨床試驗
    • Astra Zeneca-默克公司的LYNPARZA獲得歐盟核准用於胰臟癌治療

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-4342CA32667F

[198 Pages Report] The Pancreatic Cancer Therapeutics Market size was estimated at USD 4.67 billion in 2023 and expected to reach USD 5.14 billion in 2024, at a CAGR 9.95% to reach USD 9.09 billion by 2030.

Pancreatic cancer therapeutics encompass a variety of treatment modalities used to manage and combat pancreatic cancer, known for its aggressive nature and challenging prognosis. The therapeutic landscape for this malignancy includes surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, and supportive care measures that aim to relieve symptoms and improve the quality of life for patients. The need for pancreatic cancer therapeutics is driven by the increasing prevalence of the disease, attributed to factors such as aging populations, lifestyle-related risk factors, and genetic predispositions. Additionally, supportive government policies to expand access to affordable pancreatic cancer treatment have extended the scope and reach of the therapeutic options for patients. However, the complex reimbursement landscape and the inability of clinical trials to provide beneficial and credible results pose concerns about the accuracy and efficacy of the therapies. Moreover, there has been some significant progress in understanding the biology of the disease, resulting in the development of targeted therapeutics and personalized medicine approaches. These treatments are designed to interfere with specific pathways or mechanisms that promote the growth and spread of pancreatic cancer cells.

KEY MARKET STATISTICS
Base Year [2023] USD 4.67 billion
Estimated Year [2024] USD 5.14 billion
Forecast Year [2030] USD 9.09 billion
CAGR (%) 9.95%

Type: Need for rapid deployment of therapeutic options due to fast progression of exocrine pancreatic cancer

Pancreatic neuroendocrine tumors (NETs), also called endocrine pancreatic cancer or islet cell tumors, are a type of cancer associated with the rapid and abnormal growth of endocrine cells, called islet cells, in the pancreas. Treatment for this type of cancer usually involves surgery to remove the tumor cells or the major parts of the body and tail of the pancreas. Furthermore, for tumors that cannot be removed by surgery, treatment may include a combination of chemotherapy or hormone therapy. Exocrine pancreatic cancer, or adenocarcinoma, refers to cancers that form in the tissue of the pancreas, within the ducts that carry pancreatic juices and aid digestion. However, compared to endocrine pancreatic cancers, exocrine pancreatic cancers advance rapidly.

Product: Expanding number of approvals for chemotherapy treatment options

Chemotherapy remains an essential pillar in the treatment of pancreatic cancer, involving systemic drug administration to impede cancer cell proliferation. These cytotoxic medications can be taken orally or injected, and their inability to distinguish between malignant and normal cells results in side effects. However, chemotherapy is a critical component of the therapeutic regimen, employed alongside other strategies to enhance patient outcomes. Gene therapy represents a cutting-edge technique, delivering new genetic material into patients' cells to rectify defective genes responsible for cancer growth or to introduce genes that trigger an immune response against tumor cells. Presently, gene therapy for pancreatic cancer is largely exploratory and confined to clinical research, holding the promise of more precise, individualized treatments in the future. Immunotherapy is a rapidly evolving field that leverages the body's immune defenses against cancer. Pancreatic cancer treatments, including checkpoint inhibitors, therapeutic vaccines, and adoptive cell therapies, are scrutinized for their ability to target cancer cells effectively. The efficacy of immunotherapy in pancreatic cancer varies. However, ongoing investigations are assessing its potential, especially for patients with specific genetic markers. Radiation therapy, a technique employing high-energy particles to eradicate cancer cells, can serve as a solitary treatment or in combination with surgical interventions to manage pancreatic cancer. Technological advancements such as stereotactic body radiation therapy (SBRT) enhance the accuracy of radiation delivery, minimizing collateral damage to healthy tissues. Surgery is the preferred approach for early-stage pancreatic cancer, aiming to excise the tumor completely. Various surgical techniques, such as the Whipple procedure or distal pancreatectomy, are determined by the tumor's pancreatic location. The viability of surgery depends on the cancer's stage and the patient's health status, and it is typically augmented by chemotherapy and radiation to optimize results. Targeted therapy offers a more nuanced attack on cancer by pinpointing and inhibiting specific molecular abnormalities or pathways involved in tumor progression.

End-Use: Expanding presence of collaborations and R&D initiatives in research institutes for pancreatic cancer treatment

Clinics provide personalized care with a focus on chemotherapy and patient follow-up. However, hospitals are at the core of providing comprehensive care for pancreatic cancer patients as they provide advanced surgery procedures and post-operative care facilities. They are pivotal in conducting major surgical procedures such as Whipple procedures, which are essential for treating operable pancreatic cancer. Research and academic institutions collaborate with biopharmaceutical companies to develop and test new treatments. Furthermore, they provide a foundation for evidence-based practice and contribute to the overall understanding of disease management, which can translate into improved drugs and care strategies.

Regional Insights

The Americas region, particularly the United States and Canada, is characterized by the presence of a robust clinical pipeline, high healthcare expenditure, and several major pharmaceutical companies. Food and Drug Administration (FDA) has approved designations such as Fast Track, Breakthrough Therapy, and Orphan Drug to several pancreatic cancer drugs, which accelerates the regulatory approval process. European nations such as Germany, France, and the United Kingdom are characterized by the presence of heightened healthcare spending, advanced healthcare facilities, and favorable reimbursement policies. The European Medicines Agency (EMA) plays a pivotal role in endorsing new therapeutic options, positively impacting market growth. Strong research collaborations between private and public entities drive innovation in cancer therapeutic research. In APAC countries such as China, Japan, India, and South Korea, there is a growing patient population and increasing awareness regarding cancer diseases, driving the need for therapeutic options. The increase in local generic drug production in countries such as India contributes to regional market dynamics.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pancreatic Cancer Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pancreatic Cancer Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pancreatic Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Amgen Inc., Ascentage Pharma Group, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Carl Zeiss AG, Carrick Therapeutics Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Faeth Therapeutics, Inc., FUJIFILM Holdings Corporation, GE HealthCare Technologies, Inc., GenesisCare, GlaxoSmithKline PLC, Hetero Healthcare Limited, ImmunityBio, Inc., Innovent Biologics Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Mitsubishi Heavy Industries, Ltd., NGM Biopharmaceuticals, Inc., NovalGen, Novartis AG, PanTher Therapeutics, Inc., Pfizer, Inc., RenovoRx, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zentalis Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Pancreatic Cancer Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Endocrine Pancreatic Cancer
    • Exocrine Pancreatic Cancer
  • Product
    • Chemotherapy
    • Gene Therapy
    • Immunotherapy
    • Radiation Therapy
    • Surgery
    • Targeted Therapy
  • End-Use
    • Cancer Centers/Clinics
    • Hospitals
    • Research Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Pancreatic Cancer Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pancreatic Cancer Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Pancreatic Cancer Therapeutics Market?

4. What is the market share of the leading vendors in the Pancreatic Cancer Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Pancreatic Cancer Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of pancreatic cancer cases across the world
      • 5.1.1.2. Government initiatives to expand access to pancreatic cancer treatment options
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse drug recalls and difficulty in availing reimbursement options
    • 5.1.3. Opportunities
      • 5.1.3.1. Research initiatives and advancements to improve the efficacy of pancreatic cancer therapeutics
      • 5.1.3.2. Approvals for pancreatic cancer therapy and orphan drug approvals for cancer treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations and complications of pancreatic cancer treatment options and lack of trained medical professionals
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Need for rapid deployment of therapeutic options due to fast progression of exocrine pancreatic cancer
    • 5.2.2. Product: Expanding number of approvals for chemotherapy treatment options
    • 5.2.3. End-Use: Expanding presence of collaborations and R&D initiatives in research institutes for pancreatic cancer treatment
  • 5.3. Market Trend Analysis
    • 5.3.1. Advancements in pancreatic cancer therapeutics in Americas region due to strong presence of key players and supportive regulatory landscape
    • 5.3.2. Collaborative R&D activities by cancer research organization and improved support for clinical trials of novel therapies to elevate the advancements in pancreatic cancer therapeutics in the Asia-Pacific
    • 5.3.3. Concerted efforts of researchers, funding agencies, and regulatory bodies catalyzing to delivering novel pancreatic cancer therapeutic solutions across EMEA
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Pancreatic Cancer Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Endocrine Pancreatic Cancer
  • 6.3. Exocrine Pancreatic Cancer

7. Pancreatic Cancer Therapeutics Market, by Product

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Gene Therapy
  • 7.4. Immunotherapy
  • 7.5. Radiation Therapy
  • 7.6. Surgery
  • 7.7. Targeted Therapy

8. Pancreatic Cancer Therapeutics Market, by End-Use

  • 8.1. Introduction
  • 8.2. Cancer Centers/Clinics
  • 8.3. Hospitals
  • 8.4. Research Institutes

9. Americas Pancreatic Cancer Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Pancreatic Cancer Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Pancreatic Cancer Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients
    • 12.3.2. Lisata Receives Orphan Drug Designation For Pancreatic Cancer Therapy
    • 12.3.3. PanCAN Announces New & Advanced Research Investment
    • 12.3.4. Prestige Biopharma and Imagion Biosystems Sign Partnership Agreement to Develop Early Pancreatic Cancer Diagnosis Platform
    • 12.3.5. TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation
    • 12.3.6. Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics
    • 12.3.7. Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
    • 12.3.8. FDA Grants Breakthrough Therapy Designation to Zenocutuzumab for NRG1+ Pancreatic Cancer
    • 12.3.9. FDA Clears TME Pharma's IND for Pancreatic Cancer Therapy Trial
    • 12.3.10. GenesisCare Launches ViewRay MRIdian MRI-Guided Radiation Therapy System at Lee Health Regional Cancer Center
    • 12.3.11. USD 3 Million National Grant to Fund Pancreatic Cancer Study
    • 12.3.12. Leap Therapeutics Acquires Flame Biosciences
    • 12.3.13. Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
    • 12.3.14. Faeth Therapeutics Raises USD 47 million to Advance Clinical Trials for Cancer
    • 12.3.15. AstraZeneca-Merck's Lynparza Wins EU Approval for Pancreatic Cancer

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PANCREATIC CANCER THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PANCREATIC CANCER THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PANCREATIC CANCER THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. PANCREATIC CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. PANCREATIC CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PANCREATIC CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY ENDOCRINE PANCREATIC CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY ENDOCRINE PANCREATIC CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY EXOCRINE PANCREATIC CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY EXOCRINE PANCREATIC CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS/CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS/CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 52. BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 53. BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 54. BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 58. CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 59. CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 60. CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 64. MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 65. MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 66. MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 71. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 72. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 73. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 74. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 86. AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 88. AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 92. CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 93. CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 94. CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 98. INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 99. INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 100. INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 104. INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 105. INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 106. INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 110. JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 111. JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 112. JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 116. MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 117. MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 118. MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 122. PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 124. PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 128. SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 129. SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 130. SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 134. SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 136. SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 140. TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 141. TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 142. TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 146. THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 147. THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 148. THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 152. VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 153. VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 154. VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 166. DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 167. DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 168. DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 172. EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 173. EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 174. EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 178. FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 179. FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 180. FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 184. FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 185. FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 186. FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 190. GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 191. GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 192. GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 196. ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 197. ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 198. ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 202. ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 203. ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 204. ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 208. NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 209. NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 210. NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 214. NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 215. NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 216. NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 220. NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 221. NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 222. NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 226. POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 227. POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 228. POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 232. QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 233. QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 234. QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 238. RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 239. RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 240. RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 244. SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 246. SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 250. SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 256. SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 257. SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 258. SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 262. SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 263. SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 264. SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 268. SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 269. SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 270. SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 274. TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 275. TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 276. TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 286. UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 288. UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 289. PANCREATIC CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 290. PANCREATIC CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023